TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Oncolytics Biotech ( (ONCY) ) just unveiled an announcement.
On September 8, 2025, Oncolytics Biotech Inc. announced promising results from three studies on metastatic colorectal cancer (mCRC) involving their drug pelareorep. The studies demonstrated significant efficacy, with pelareorep showing prolonged survival benefits and immune activation in KRAS mutant mCRC patients. The company plans to advance regulatory discussions and initiate an investigator-sponsored trial to further explore pelareorep’s potential in this patient population, potentially positioning the drug as a leading immunotherapy in gastrointestinal cancers.
The most recent analyst rating on (ONCY) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent. The company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors for the treatment of various cancers, including metastatic pancreatic, breast, and other gastrointestinal tumors. Oncolytics is actively seeking strategic partnerships to enhance development and commercial impact.
Average Trading Volume: 1,138,462
Technical Sentiment Signal: Buy
Current Market Cap: $107.3M
See more data about ONCY stock on TipRanks’ Stock Analysis page.